Related Experiment Video
Updated: Feb 26, 2026

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells
Published on: May 18, 2018
TNFR2 signaling promotes monocytic-MDSC differentiation and production of immunosuppressive mediators
Yuta Tsuji1, Masaki Inoue1, Tomoya Okuda1
1The Faculty of Pharmaceutical Sciences, Laboratory of Cellular and Molecular Physiology, Kobe Gakuin University, Japan.
Abstract:
Myeloid-derived suppressor cells (MDSCs) differentiate and proliferate in the pathological context of cancer, suppress T-cell responses, and promote tumor progression and therapeutic resistance. These cells express high levels of TNF receptor type 2 (TNFR2), but the ligand TNF-α also activates TNFR1, masking TNFR2-specific function. We analyzed TNFR2 signaling using GM-CSF-induced MDSCs from TNFR2-knockout mice and scR2agoTNF-Fc, a TNFR2-selective agonist. Stimulation with scR2agoTNF-Fc maintained a highly suppressive monocytic subset. TNFR2 deficiency reduced MDSC-mediated T-cell suppression. TNFR2 activation also increased the expression of immunosuppressive effector molecules such as inducible nitric-oxide synthase and interleukin-10. These results indicate that TNFR2 is a promising therapeutic target for modulating the differentiation and immunosuppressive functions of MDSC subsets.
Insights
Tumor-promoting myeloid-derived suppressor cells (MDSCs) rely on TNF receptor type 2 (TNFR2) signaling. Targeting TNFR2 can modulate MDSC function and potentially enhance cancer therapy by reducing immunosuppression.
Area of Science:
- Immunology
- Cancer Biology
- Cell Signaling
Background:
- Myeloid-derived suppressor cells (MDSCs) are key regulators of the tumor microenvironment, promoting cancer progression and therapeutic resistance.
- MDSCs express high levels of TNF receptor type 2 (TNFR2), but its specific function is obscured by the dual action of TNF-α on TNFR1 and TNFR2.
Purpose of the Study:
- To investigate the specific role of TNFR2 signaling in the function and differentiation of MDSCs.
- To evaluate TNFR2 as a potential therapeutic target for modulating MDSC-mediated immunosuppression in cancer.
Main Methods:
- Utilized TNFR2-knockout mice to generate GM-CSF-induced MDSCs.
- Employed a TNFR2-selective agonist (scR2agoTNF-Fc) to stimulate MDSCs.
- Assessed the impact of TNFR2 modulation on MDSC suppressive capacity and effector molecule expression.
Main Results:
- TNFR2 activation maintained a highly suppressive monocytic MDSC subset.
- TNFR2 deficiency significantly reduced MDSC-mediated suppression of T-cell responses.
- TNFR2 signaling upregulated key immunosuppressive molecules, including inducible nitric-oxide synthase (iNOS) and interleukin-10 (IL-10).
Conclusions:
- TNFR2 plays a critical role in maintaining the immunosuppressive functions of MDSCs.
- Targeting TNFR2 represents a promising therapeutic strategy to counteract MDSC-driven immune suppression in cancer.
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
TGF - β Signaling Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...

